Tumor-associated vascular endothelium (TEC) (TEC)

The tumor-associated vascular endothelium refers to the specialized layer of endothelial cells lining the blood vessels that supply a tumor. Unlike normal vasculature, tumor vessels are often disorganized, leaky, and characterized by rapid proliferation and altered expression of surface markers such as CD105 and CD31 (Source: PubMed, PMID: 15607511). This compartment is a critical therapeutic target in oncology, as tumors require a dedicated blood supply for growth beyond a few millimeters (Source: NIH, National Cancer Institute). Drugs targeting this endothelium generally fall into two categories: anti-angiogenic agents and vascular disrupting agents (VDAs). Anti-angiogenic agents inhibit the formation of new vessels by blocking pathways like VEGF/VEGFR, while VDAs selectively damage the established tumor cytoskeleton to cause vessel collapse and subsequent tumor necrosis (Source: PubMed, PMID: 21832109). Clinical use of these agents is often limited by systemic toxicities including hypertension and impaired wound healing (Source: FDA). This target remains a cornerstone of combination therapies in various solid tumors.

Other names

Tumor vasculatureTumor endothelial cellsTumor blood vesselsNeovasculature

Inhibition of the Vascular Endothelial Growth Factor (VEGF) signaling pathway to suppress neoangiogenesis, or the induction of microtubule depolymerization and actin cytoskeleton reorganization in endothelial cells to cause the physical collapse of existing tumor vasculature (Source: PubMed, PMID: 21832109; Source: PubMed, PMID: 15607511).